Malcolm Finlayson
8 Papers
14 Citations
Malcolm Finlayson is an academic researcher. The author has contributed to research in topics: CD44 & Cancer cell. The author has an hindex of 3, co-authored 7 publications.
Chat about Author
Papers
A6 Peptide Activates CD44 Adhesive Activity, Induces FAK and MEK Phosphorylation, and Inhibits the Migration and Metastasis of CD44-Expressing Cells
Randolph S. Piotrowicz,Bassam B. Damaj,Mohamed Hachicha,Francesca Incardona,Stephen B. Howell,Malcolm Finlayson +5 more
TL;DR: A6 potently blocks the migration of CD44-positive cells in vitro through an interaction with CD44 that alters its structure and activates CD44 to enhance ligand binding and downstream signaling, suggesting that CD44 activation may represent a novel strategy for inhibiting metastatic disease.
65
Phase I trial of daily subcutaneous SPL-108 injections in combination with paclitaxel in patients with platinum resistant CD44+ advanced ovarian epithelial cancer
Eugenia Girda,Jun Hou,David M. Nelson,Malcolm Finlayson,Alexandre Buckley de Meritens,Marina Chekmareiva,Aliza Leiser,Mihae Song,Ruth Stephenson,Nancy Chan,Ana I. Tergas,Reena Vattakalam,Jason D. Wright,Hua Yu,Antons Martincuks,A. Kohut,Joycelynne Palmer,Lorna Rodriguez-Rodriguez +17 more
TL;DR: The combination of SPL-108 with weekly paclitaxel was safe and well tolerated, andEncouraging antitumor activity was observed, with 72% of patients deriving a clinical benefit.
Patent
Compositions and methods for modulation of cell migration
Malcolm Finlayson,Bassam B. Damaj +1 more
- 05 Mar 2010
TL;DR: A method of treating a disease characterized by aberrant cell migration and/or invasion includes administering to a subject an effective amount of the peptide of SEQ ID NO:3 or an Å6 polypeptide to bind to a CD44 polypeptic and modulate signal transduction activity for a sufficient period of time to treat the disease.
5
Patent
Modulation of intracellular signaling
Malcolm Finlayson,Bassam B. Damaj +1 more
- 04 Mar 2011
TL;DR: In this paper, a method of diagnosing a condition characterized by aberrant cell migration and/or invasion is presented. But, the method is limited to the detection of aberrant cells migration and invasion.
4
A6 Peptide Is Selectively Cytotoxic For Chronic Lymphocytic Leukemia Cells
Suping Zhang,Hsien Lai,Grace Liu,Laura Z. Rassenti,Michael Y. Choi,Stephen B. Howell,Malcolm Finlayson,Thomas J. Kipps +7 more
TL;DR: Clinical studies have found the A6 peptide to be well-tolerated and without dose-limiting toxicity in patients with solid tumors who have been treated to date, and a clinical study is planned to evaluate the safety and activity of the A 6 peptide in the treatment of patients with CLL.
3